About this trial
Psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are chronic inflammatory diseases within the spectrum of spondyloarthritis, characterized by immune-mediated inflammation and progressive functional impairment. Meteorin-like protein (Metrnl) is a novel adipomyokine with potential immunomodulatory and anti-inflammatory properties; however, its role in spondyloarthritis remains incompletely understood. This study aims to evaluate serum Metrnl levels in patients with PsA and AS compared with healthy controls and to investigate their association with disease activity, inflammatory markers, and clinical manifestations. The findings may provide insights into the potential role of Metrnl as a biomarker of disease activity and inflammation in spondyloarthritis.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
patients diagnosed with ankylosing spondylitis (AS)and psoriatic arthritis (PsA), in addition to age- and sex-matched healthy controls.
Disqualifiers
None
Trial population
AS diagnosed according to the modified New York criteria, while PsA diagnosed based on the CASPAR criteria,
Trial design
Cohort
Cross-sectional
Treatments tested in this trial
IL 41
Diagnostic testSerum levels of meteorin-like protein (Metrnl) will be measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's instructions.
Treatment groups
Trial outcomes
Primary outcomes
• Serum IL41 differences among AS, PsA, and controls
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: